After months of deliberations, a court in Iowa has opted to fine contract manufacturing company Cambrex $6,000 for safety violations after an explosion at its facility in Charles City.
Almac Sciences of Northern Ireland has introduced a new business unit covering solid state chemistry in a move that addresses a missing link in its technology portfolio.
Pfizer is shifting its research focus to those diseases where its sees the potential for the biggest treatment improvements and profits, while dropping eight disease areas including cholesterol.
French firm Novasep has significantly boosted its ability to provide customers with enantiomerically pure compounds with the addition of a new chiral chromatography unit.
Capsule specialist Capsugel has won the contract to make a highly-touted new anti-inflammatory developed by French biotechnology company NicOx as the product approaches registration.
Indian pharmaceutical companies are making their first forays in the biotechnology arena, helping the market expand from a standing start at the beginning of the decade to reach a value of $2bn in 2006-7, according to a recent report from KPMG.
UK-based Melbourn Scientific is now offering an integrated package of formulation, method development, analysis and short-run clinical manufacture services to industrial clients.
Outsourcing-Pharma.com presents its latest round-up of new appointments, employment moves and personnel news in the pharmaceutical contract services sector.
India’s contract manufacturing market is expected to rocket forward over the next couple of years to reach a value of $2.46bn in 2010, according to a just-released report from KPMG.
US packaging specialist West Pharmaceutical Services has carried the earnings momentum it generated in the first three months of the year through to the second quarter.
Outsourcing-Pharma.com presents its periodic round-up of personnel changes in the pharmaceutical outsourcing arena, with senior appointments at Bristol-Myers Squibb, Parexel and GVK Bio, amongst others.
Pharmaceutical companies in the developed world have already
shifted substantial manufacturing and clinical trial work to
emerging economies such as China and India, but a new study suggest
they are increasingly counting on these...
Outsourcing-Pharma.com presents its latest round-up of news in the
contract development and manufacturing sector, with updates from
Rentschler Biotechnologie, Eden Biodesign, Emcure Pharmaceuticals
and new start-up Appian Labs.
Ireland's Almac Group has announced the creation of a new oncology
division that will focus on the discovery and development of "novel
and innovative" approaches to treatment in this key disease area.
Canadian contract manufacturer and consultancy firm PharmEng
International has published its 2007 accounts, and says it remains
firmly focused on getting into the black in 2008.
Irish drugmaker Elan is considering a separate stock exchange
listing for its contract services unit, Elan Drug Technology,
according to comments by executives at its recent annual general
meeting.
2005 marked the real beginning of contract manufacturing in Japan,
which had been held back by an overly-cautious regulatory
environment and significant and unique quality and specification
demands in the marketplace.
Overall, 2007 was another stellar year for contract service
providers, particularly those at the early-stage end of
development, although companies are advised to watch out for a
tougher environment ahead.
Jubilant Organosys, India's largest custom research and
manufacturing services (CRAMS) provider, has scored new contracts
to the tune of $92m for the year thus far as its business continues
to gather momentum.
An investigation in the aftermath of a fire and explosion at one of
Cambrex' US plants last year has found the firm in breach of
several safety regulations and the company will be fined
accordingly.
Four of India's biggest vaccine manufacturers have had their
licenses suspended by the Indian government after failing to meet
good manufacturing practise (GMP) requirements, according to local
media reports.
An Indian contract research and manufacturing services (CRAMS) firm
is planning to plant its roots in the US to try and drum up more
business in this lucrative market.
Another sharp decline in biomedical production saw overall
manufacturing output in Singapore fall for the second month running
in December, prompting fears that the heavily trade-reliant economy
could buckle under a looming US recession.
Lonza has revealed a profit hike for the full year of 2007,
reflecting the fruit of its "revised growth strategies"
across its business units, said the firm, which also announced its
"innovations" for future growth...
Product recalls in the UK due to health and safety concerns have
shot up to their highest level, with the rise in outsourcing to
China finger pointed for much of the blame.
Chemical and intermediates firm Lanxess has announced that its
subsidiary Saltigo is the proud new owner of a site in Washington
in the US, formerly used by Eli Lilly subsidiary, ICOS.
Japan's number two pharma firm has elected to set up significant
operations in India - the first Japanese pharma company planning to
plant itself in the country on such a scale.
Roche today announced a handful of new charitable technology
transfer agreements with manufacturers in Africa and Asia, allowing
local production of generic HIV drugs.
UK-based William Ransom & Son has a shaky future ahead
following a disappointing and unacceptable six-month financial
report, compounded by a suspension of the companys manufacturing
license.
Siegfried has signed a $27.7m contract with Arena Pharmaceuticals
to manufacture Arena's Phase III oral obesity drug candidate
lorcaserin hydrochloride.
Patheon has finally revealed its plans to tackle the ongoing
problems it has been facing with its Puerto Rican operations, which
are draining the firm of profitability.
The first steps in tightening the safety controls on the
pharmaceutical ingredients imported to the US from China have been
taken following months of negotiations between the regulatory
bodies of the two countries.
Bristol-Myers Squibb (BMS) has finally detailed its plans to trim
the fat and save cash, months after first revealing that big
changes would be on the cards.
Sanofi-Aventis has opened its first Asian research and development
centre in Goa, India, signalling its ambition to further tap in to
this region's budding pharma scene.
Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract
Lonza Drug Product expert Léa Sorret PhD explores Clinical In-Use Testing of Biotherapeutics in this white paper. Léa shares her expertise and describes...